Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cardiol Therapeutics ( (TSE:CRDL) ) has issued an update.
On May 7, 2026, Cardiol Therapeutics reported that results from its Phase II MAvERIC study of CardiolRx™ in recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association. The peer-reviewed data show rapid and sustained reductions in pericarditis pain and inflammation, fewer annual recurrences, and a favorable safety profile, providing clinical rationale for the pivotal Phase III MAVERIC trial, which has passed 75% enrollment and could strengthen Cardiol’s position in addressing a significant unmet need in recurrent pericarditis and other inflammation-driven heart diseases.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$8.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, sizable losses, and sustained cash burn), partially offset by a low-debt balance sheet. Technicals are a positive contributor with an improving uptrend and constructive momentum, while valuation remains constrained due to negative earnings and no dividend support.
To see Spark’s full report on CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule drug candidate, CardiolRx™, targets inflammasome pathway activation implicated in pericarditis, myocarditis, and heart failure, and the company is also advancing CRD-38, a subcutaneous therapy for inflammatory heart disease, including heart failure.
Average Trading Volume: 136,352
Technical Sentiment Signal: Buy
Current Market Cap: C$203.6M
See more data about CRDL stock on TipRanks’ Stock Analysis page.
